Trials / Conditions / Vaccines, Pneumococcal Conjugate Vaccine

Vaccines, Pneumococcal Conjugate Vaccine

9 registered clinical trials studyying Vaccines, Pneumococcal Conjugate Vaccine.

Status	Trial	Sponsor	Phase
Completed	Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal NCT00980655	Pfizer	Phase 3
Completed	Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil NCT00676091	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects NCT00500357	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants NCT00574795	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants NCT00475033	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent) NCT00683410	Wyeth is now a wholly owned subsidiary of Pfizer	—
Completed	Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects NCT00269672	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 2
Completed	Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children NCT00580684	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4
Completed	Study Evaluating Prevenar Immunogenicity in High Risk Children NCT00581620	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4